VEGFC and Alzheimer disease: Therewas a 1.5-fold and a 1.6-fold increase in MVD in the AD-VEGF-C-treated mice andVEGF-C156S-treated mice compared to the DSS-treated mice (57.6±2.9 to 37.8±2.9, and56.6±2.6 to 34.8±3.1, respectively; both P<0.001; Figure 4B and C).